✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Trehalose is an investigational drug.
There have been 17 clinical trials for Trehalose. The most recent clinical trial was a Phase 2 trial, which was initiated on November 9th 2021.
The most common disease conditions in clinical trials are Alzheimer Disease, Macular Edema, and Keratoconjunctivitis Sicca. The leading clinical trial sponsors are Mashhad University of Medical Sciences, Seelos Therapeutics, Inc., and Bioblast Pharma Ltd.
There are four hundred and thirty US patents protecting this investigational drug and twenty-nine international patents.
Recent Clinical Trials for Trehalose
|SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease||Seelos Therapeutics, Inc.||Phase 2|
|SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease||Neuroscience Trials Australia||Phase 2|
|Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease||Neuromed IRCCS||Phase 4|
Top disease conditions for Trehalose
Top clinical trial sponsors for Trehalose
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Trehalose||See Plans and Pricing||Phosphonate compounds for treatment of medical disorders||Achillion Pharmaceuticals, Inc. (New Haven, CT)||See Plans and Pricing|
|Trehalose||See Plans and Pricing||Double-acylated GLP-1 derivatives||Novo Nordisk A/S (Bagsvaerd, DK)||See Plans and Pricing|
|Trehalose||See Plans and Pricing||Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer||Capella Therapeutics, Inc. (San Diego, CA)||See Plans and Pricing|
|Trehalose||See Plans and Pricing||Polymeric nanoparticles and methods of making and using same||Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Trehalose||World Intellectual Property Organization (WIPO)||WO2013170005||2032-05-11||See Plans and Pricing|
|Trehalose||Taiwan||TW201718611||2035-08-26||See Plans and Pricing|
|Trehalose||World Intellectual Property Organization (WIPO)||WO2017035357||2035-08-26||See Plans and Pricing|
|Trehalose||China||CN104519902||2032-05-08||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|